These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19147251)

  • 21. Formulary expansion to provide access to medications prescribed by a specialist in a low-income population.
    Robbins C; Stillwell T; Wilson S; Fitzgerald L
    J Health Care Poor Underserved; 2012 May; 23(2):834-41. PubMed ID: 22643627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reflections on a month in the life of the Ontario Drug Benefit Plan.
    McIsaac W; Naylor CD; Anderson GM; O'Brien BJ
    CMAJ; 1994 Feb; 150(4):473-7. PubMed ID: 8313259
    [No Abstract]   [Full Text] [Related]  

  • 24. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New diabetes medications drive up costs and stymie formulary design.
    Reinke T
    Manag Care; 2012 Apr; 21(4):16-8. PubMed ID: 22590782
    [No Abstract]   [Full Text] [Related]  

  • 27. Fixed and flexible formularies as cost-control mechanisms.
    Dewa CS; Hoch JS
    Expert Rev Pharmacoecon Outcomes Res; 2003 Jun; 3(3):303-15. PubMed ID: 19807378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The multiple insurance drug formulary for the urologic nurse.
    McQuiston M
    Urol Nurs; 1997 Dec; 17(4):154-5. PubMed ID: 9451244
    [No Abstract]   [Full Text] [Related]  

  • 29. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
    Lexchin J; Mintzes B
    Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How cheap are Canada's drugs really?
    Hollis A
    J Pharm Pharm Sci; 2004 Jun; 7(2):215-6. PubMed ID: 15367378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superior hospital formularies: a critical analysis.
    Rucker TD
    Hosp Pharm; 1982 Sep; 17(9):465-71, 474-5, 477-9 passim. PubMed ID: 10257551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
    Garattini L; Cornago D; De Compadri P
    Health Policy; 2007 Aug; 82(3):330-9. PubMed ID: 17125881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicare program: Medicare Advantage and prescription drug programs MIPPA drug formulary & protected classes policies. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Jan; 74(11):2881-8. PubMed ID: 19385109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia.
    Marra F; Patrick DM; White R; Ng H; Bowie WR; Hutchinson JM
    J Antimicrob Chemother; 2005 Jan; 55(1):95-101. PubMed ID: 15590717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ontario's formulary committee: how recommendations are made.
    PausJenssen AM; Singer PA; Detsky AS
    Pharmacoeconomics; 2003; 21(4):285-94. PubMed ID: 12600223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
    Laupacis A
    CMAJ; 2002 Jan; 166(1):44-7. PubMed ID: 11800247
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.